CD163 and cancer: We observed that a robust TAAs expression together with a favorable immune infiltrate contexture inside the tumor (high intratumoral CD8 + cells/low FOXP3 + Treg and CD163 + myeloid cells) improve the vaccine ability to protect pts from cancer recurrence.